• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022
MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1174-1181. doi: 10.15585/mmwr.mm7137a3.ABSTRACTThe 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer, Inc]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Merck Sharp & Dohme LLC]) have been recommended for U.S. children, and the recommendations vary by age group and risk group (1,2). In 2021, 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sharp & Dohme LLC]) was licensed for use in adults aged ≥18 years (3). On June 17, 2022, the Food and Drug Administration (FDA) appro...
Source: MMWR Morb Mortal Wkl... - September 15, 2022 Category: Epidemiology Authors: Miwako Kobayashi Jennifer L Farrar Ryan Gierke Andrew J Leidner Doug Campos-Outcalt Rebecca L Morgan Sarah S Long Katherine A Poehling Adam L Cohen ACIP Pneumococcal Vaccines Work Group CDC Contributors Source Type: research

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data
Clin Cosmet Investig Dermatol. 2022 Jun 3;15:1037-1043. doi: 10.2147/CCID.S267217. eCollection 2022.ABSTRACTAtopic dermatitis (AD) is a chronic inflammatory skin disease that greatly impacts patient quality of life. Type 2 cytokine interleukin (IL)-13 is integral to the pathogenesis of AD. Tralokinumab is a fully human IgG4 monoclonal antibody that specifically targets IL-13, preventing downstream signaling of inflammatory pathways that may contribute to AD. Tralokinumab was US Food and Drug administration (FDA) recently approved for the treatment of moderate to severe AD on December 28, 2021. In our review, we will explor...
Source: Clinical, Cosmetic and Investigational Dermatology - June 10, 2022 Category: Dermatology Authors: Katherine A Kelly Patrick O Perche Steven R Feldman Source Type: research

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):109-117. doi: 10.15585/mmwr.mm7104a1.ABSTRACTIn 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years, based on studies that compared antibody responses to PCV20 and PCV15 with those to 13-valent PCV (PCV13) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.). Antibody responses to two additional serotypes included in PCV15 were compared to corresponding responses after PCV13 v...
Source: MMWR Morb Mortal Wkl... - January 27, 2022 Category: Epidemiology Authors: Miwako Kobayashi Jennifer L Farrar Ryan Gierke Amadea Britton Lana Childs Andrew J Leidner Doug Campos-Outcalt Rebecca L Morgan Sarah S Long H Keipp Talbot Katherine A Poehling Tamara Pilishvili Source Type: research

Flu Shot May Help Protect Diabetics From CV Hospitalization
This study shows that it may significantly reduce cardiovascular illness and death during flu season, and thus it is very important for this high-risk population to get vaccinated, she stressed. Dr Jacob A Udell (Peter Munk Cardiac Centre and Cardiovascular Division, University Health Network, and University of Toronto, ON), who was not involved with this study, agrees. These observational data provide " positive reinforcement of why we should be getting patients vaccinated, particularly patients who aren ' t over 65 but have diabetes, " he told heart wire . Before flu season starts, cardiologists, internists, and endoc...
Source: Dr Portnay - July 26, 2016 Category: Cardiology Authors: Dr Portnay Source Type: blogs

Notes from the Field: Administration Error Involving a Meningococcal Conjugate Vaccine - United States, March 1, 2010-September 22, 2015.
Abstract Menveo (GlaxoSmithKline, previously Novartis AG) is a conjugate vaccine that was recommended in October 2010 for routine use in adolescents (preferably aged 11 or 12 years, with a booster at 16 years), and among persons aged 2 through 54 years with certain immunosuppressive conditions, to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (1). These recommendations have since been updated (2). Menveo is supplied in two vials that must be combined before administration. The MenA lyophilized (freeze-dried) component must be reconstituted with the MenCYW-135...
Source: MMWR Morb Mortal Wkl... - February 20, 2016 Category: Epidemiology Authors: Su JR, Miller ER, Duffy J, Baer BM, Cano MV Tags: MMWR Morb Mortal Wkly Rep Source Type: research